$386.00
N/A
Last update: Nov 11, 4:00 PM
Bio-Rad Laboratories Inc
BIONYSE
Bio-Rad Laboratories rose 17.9% from $327.28 to $386.00, ahead of the S&P 500's +11.2%. Its worst day was Feb 13 (−12.3%), and its low came May 12 at $241.71.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $2.51 missed the $2.65 estimate on $693.2M revenue (est. $689.9M); FY revenue guidance of $2.6B–$2.6B against the $2.6B consensus.
−12.3%, the year's worst day · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Bio-Rad Laboratories shares fell 6.4%, while the S&P 500 fell 0.4%.
−6.4% · S&P 500 −0.4%
EPS of $1.89 missed the $2.14 estimate on $592.1M revenue (est. $587.4M); FY revenue guidance of $2.5B–$2.6B against the $2.6B consensus.
−8.4% · S&P 500 +0.3%
Bio-Rad Laboratories closed at its lowest level of the year, 26.1% below where the year started.
−0.9% · S&P 500 −0.2%
Bio-Rad Laboratories shares rose 6.5%, while the S&P 500 rose 0.1%.
+6.5% · S&P 500 +0.1%
EPS of $2.62 beat the $1.86 estimate on $651.0M revenue (est. $630.7M); FY revenue guidance of $2.5B–$2.6B against the $2.6B consensus.
+4.5% · S&P 500 −0.2%
Bio-Rad Laboratories closed at its highest level of the year, 19.3% above where the year started.
+2.2% · S&P 500 +0.3%
Bio-Rad Laboratories shares fell 5.9%, while the S&P 500 rose 0.2%.
−5.9% · S&P 500 +0.2%
EPS of $2.65 beat the $2.30 estimate on $656.4M revenue (est. $652.3M); FY revenue guidance of $2.5B–$2.6B against the $2.6B consensus.
−2.9% · S&P 500 −4.4%
Where it ended: a close of $386.00 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $2.78, revenue est. $692.6M).
Nothing in the past 12 months.
All BIO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BIO and SPY from Benzinga historical bars. Not investment advice.
